A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BMS-986168 in Participants with Progressive Supranuclear Palsy
ID Number 17-1126Principal Investigator(s)
Department(s) or Division(s)
The purpose of this study is to evaluate the safety, effectiveness and tolerability (level of side effects) of an experimental drug called BMS-986168, being developed for the treatment of Progressive Supranuclear Palsy (PSP). BMS-986168 is not approved by the United States Food and Drug Administration (FDA) to treat PSP. In this study, BMS-986168 will be compared to placebo which does not contain any active ingredient. The study will also measure the amount of study drug in the blood, determine how the immune system reacts to BMS-986168, and check other areas of health and disease that may be related to BMS-986168. BMS-986168 is believed to slow the progression of PSP disease.
Recruiting Patients: Yes